[Covalent drug discovery exploiting the new warheads].

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Drug Discovery

Background:

• Covalent drugs irreversibly inhibit target proteins by forming covalent bonds.
• Developing safe and selective covalent drugs requires innovative reaction chemistry.
• Current research focuses on enhancing target selectivity in covalent drug design.

Purpose of the Study:

• To introduce novel reactive groups, α-chlorofluoroacetamide and bicyclobutane amide, for covalent drug development.
• To explore the application of these new groups in creating targeted covalent inhibitors.
• To advance the development of safer and more effective treatments for cancer and infectious diseases.

Main Methods:

• Design and synthesis of α-chlorofluoroacetamide and bicyclobutane amide derivatives.
• Evaluation of reactivity and selectivity towards protein targets, particularly cysteine residues.
• Application of these novel reactive groups in the development of targeted covalent inhibitors.

Main Results:

• Demonstrated the potential of α-chlorofluoroacetamide and bicyclobutane amide as effective reactive groups for protein modification.
• Achieved high target selectivity for specific proteins, crucial for minimizing off-target effects.
• Showcased the applicability of these chemistries in developing covalent inhibitors for cancer and infectious diseases.

Conclusions:

• α-chlorofluoroacetamide and bicyclobutane amide represent promising new chemistries for targeted covalent drug development.
• These novel reactive groups offer a pathway to enhanced safety and efficacy in covalent therapeutics.
• Further research holds potential for significant advancements in treating cancer and infectious diseases with targeted covalent inhibitors.